CY1106148T1 - PHARMACEUTICAL COMPOSITION PEPILAMVANOUS N-((1-N-BUTYL-4-PIPEPIDINYL) METHYL)-3,4-DIHYDRO-2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE OR SALT AND METHOD FOR FRIDAY SHE RECEIVING DRY GRANULATION - Google Patents
PHARMACEUTICAL COMPOSITION PEPILAMVANOUS N-((1-N-BUTYL-4-PIPEPIDINYL) METHYL)-3,4-DIHYDRO-2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE OR SALT AND METHOD FOR FRIDAY SHE RECEIVING DRY GRANULATIONInfo
- Publication number
- CY1106148T1 CY1106148T1 CY20061101205T CY061101205T CY1106148T1 CY 1106148 T1 CY1106148 T1 CY 1106148T1 CY 20061101205 T CY20061101205 T CY 20061101205T CY 061101205 T CY061101205 T CY 061101205T CY 1106148 T1 CY1106148 T1 CY 1106148T1
- Authority
- CY
- Cyprus
- Prior art keywords
- salt
- dry granulation
- pharmaceutical composition
- granules
- oxazino
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 150000003839 salts Chemical class 0.000 title abstract 5
- 238000007908 dry granulation Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- KVCSJPATKXABRQ-UHFFFAOYSA-N piboserod Chemical compound C1CN(CCCC)CCC1CNC(=O)C(C1=CC=CC=C11)=C2N1CCCO2 KVCSJPATKXABRQ-UHFFFAOYSA-N 0.000 abstract 6
- 239000008187 granular material Substances 0.000 abstract 4
- 238000007906 compression Methods 0.000 abstract 2
- 230000006835 compression Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 abstract 1
- 235000019700 dicalcium phosphate Nutrition 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 238000003801 milling Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229950007988 piboserod Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Abstract
Η εφεύρεση παρέχει μέθοδο για παρασκευή μιας φαρμακευτικής σύνθεσης που περιλαμβάνει Ν-((1-κβουτυλ-4-πιπεριδινυλ)μεθυλ]-3,4-διϋδρο-2Η-(1,3)οξαζινο[3,2-a]ινδολο-10-καρβοξαμίδιο (SB 207266) (piboserod) ή φαρμακευτικώς αποδεκτό άλας αυτού σε συνδυασμό με ένα ή περισσότερα φαρμακευτικώς αποδεκτά έκδοχα, η δε μέθοδος περιλαμβάνει σχηματισμό τμήματος ή του συνόλου του SB 207266 ή του άλατος αυτού σε κόκκους με μια μέθοδο ξηρής κοκκοποίησης. Η μέθοδος κατά προτίμηση είναι μια μέθοδος συμπίεσης κυλίνδρου, που ακολουθείται κατά προτίμηση από άλεση προς κατάλληλο μέγεθος σωματιδίου. Οι κόκκοι συνήθως είναι αυξημένου μεγέθους σωματιδίου ή/και συμπιεσμένοι εν συγκρίσει προς το SB 207266 ή το άλας αυτού. Κατά προτίμηση, το SB 207266 ή το άλας αυτού υπάρχει στη σύνθεση ή/και στους κόκκους σε τουλάχιστον 4 % κατά βάρος ή/και μέχρι 60% κατά βάρος της σύνθεσης ή/και κατά βάρος των κόκκων αντιστοίχως. Ένα ενδοκοκκώδες λιπαντικό, πληρωτικό (π.χ., CaHPO4) ή/και βοηθητικό συμπίεσης (π.χ., μικροκρυσταλλική κυτταρίνη) χρησιμοποιούνται συνήθως. Η εφεύρεση παρέχει επίσης μια φαρμακευτική σύνθεση λαμβανόμενη με τη μέθοδο ξηρής κοκκοποίησης ή/και η οποία έχει παρασκευασθεί με τη μέθοδο ξηρής κοκκοποίησης.The invention provides a method for preparing a pharmaceutical composition comprising N-((1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-(1,3)oxazino[3,2-a]indole-10 -carboxamide (SB 207266) (piboserod) or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable excipients, the method comprising forming part or all of SB 207266 or its salt into granules by a dry granulation method. preferably is a roll compression method, preferably followed by milling to an appropriate particle size. The granules are typically of increased particle size and/or compressed compared to SB 207266 or its salt. Preferably, SB 207266 or its salt thereof is present in the composition and/or in the granules at least 4% by weight and/or up to 60% by weight of the composition and/or by weight of the granules respectively An intragranular lubricant, filler (e.g., CaHPO4) and/or compression aid (eg, microcrystalline cellulose) are commonly used. The invention also provides a pharmaceutical composition obtained by the dry granulation method and/or which has been prepared by the dry granulation method.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0203526A GB0203526D0 (en) | 2002-02-14 | 2002-02-14 | Process and composition |
| GB0203528A GB0203528D0 (en) | 2002-02-14 | 2002-02-14 | Process and composition |
| PCT/GB2003/000217 WO2003068193A1 (en) | 2002-02-14 | 2003-01-22 | Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106148T1 true CY1106148T1 (en) | 2011-06-08 |
Family
ID=27736214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101205T CY1106148T1 (en) | 2002-02-14 | 2006-08-28 | PHARMACEUTICAL COMPOSITION PEPILAMVANOUS N-((1-N-BUTYL-4-PIPEPIDINYL) METHYL)-3,4-DIHYDRO-2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE OR SALT AND METHOD FOR FRIDAY SHE RECEIVING DRY GRANULATION |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20050075335A1 (en) |
| EP (1) | EP1476136B1 (en) |
| JP (1) | JP2005523276A (en) |
| KR (1) | KR100967782B1 (en) |
| AT (1) | ATE329581T1 (en) |
| AU (1) | AU2003202058B2 (en) |
| BR (1) | BR0307666A (en) |
| CA (1) | CA2475659A1 (en) |
| CO (1) | CO5611095A2 (en) |
| CY (1) | CY1106148T1 (en) |
| DE (1) | DE60306120T2 (en) |
| DK (1) | DK1476136T3 (en) |
| ES (1) | ES2263949T3 (en) |
| HK (1) | HK1072359A1 (en) |
| IS (1) | IS2393B (en) |
| MX (1) | MXPA04007857A (en) |
| NO (1) | NO20043834L (en) |
| NZ (1) | NZ534333A (en) |
| PL (1) | PL206544B1 (en) |
| PT (1) | PT1476136E (en) |
| RU (1) | RU2329789C2 (en) |
| WO (1) | WO2003068193A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| CA2406592C (en) * | 2002-10-04 | 2003-09-30 | Duchesnay Inc. | Method of preparing pharmaceutical dosage forms containing multiple active ingredients |
| AR050253A1 (en) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | COMPOSITE DERIVED FROM INDAZOL CARBOXAMIDE, COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| RU2008147668A (en) * | 2006-05-04 | 2010-06-10 | Новартис АГ (CH) | METHOD FOR PRODUCING PHARMACEUTICAL COMPOSITIONS BY PRESSING BY HEATED ROLLERS |
| AR065804A1 (en) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT |
| DK2170292T3 (en) * | 2007-06-22 | 2014-04-07 | Bristol Myers Squibb Holdings Ireland | Tablet-containing Atazanavir Compositions |
| CN101772304B (en) * | 2007-07-31 | 2014-07-09 | 卡吉尔公司 | Direct compressible dextrose |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| TW201129386A (en) * | 2009-11-05 | 2011-09-01 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| TWI461213B (en) | 2009-11-05 | 2014-11-21 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| RU2564922C2 (en) * | 2011-04-19 | 2015-10-10 | Григорий Яковлевич ЛЕГИН | Composition for manufacturing sporocidal compositions of peracetic acid (versions) and set for its realisation |
| US9606054B2 (en) | 2013-09-30 | 2017-03-28 | Advantest Corporation | Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles |
| US9417181B2 (en) * | 2014-05-08 | 2016-08-16 | Advantest Corporation | Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control |
| KR101545268B1 (en) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | Tablet and method of preparing the same |
| WO2016126012A1 (en) * | 2015-02-05 | 2016-08-11 | Boryung Pharmaceutical Co., Ltd | Tablet and method of preparing the same |
| CN104945303B (en) * | 2015-06-15 | 2017-09-29 | 浙江工业大学 | The preparation method of 3 alkenyl Benzazole compounds |
| AU2021260109A1 (en) * | 2020-04-24 | 2022-12-15 | Astrazeneca Ab | Pharmaceutical formulations |
| KR102499289B1 (en) * | 2022-04-15 | 2023-02-14 | 주식회사 비에스앤코 | Manufacturing method of powder toothpaste |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3134719A (en) * | 1962-04-05 | 1964-05-26 | American Cyanamid Co | Calcium phosphates in tablet compressing |
| US5066441A (en) * | 1980-12-12 | 1991-11-19 | Rhone-Poulenc Basic Chemicals Co. | Process for compacting a calcium phosphate composition |
| US4597969A (en) * | 1982-04-05 | 1986-07-01 | Merck Sharp & Dohme | Stabilization of unstable drugs or food supplements |
| US4713245A (en) * | 1984-06-04 | 1987-12-15 | Mitsui Toatsu Chemicals, Incorporated | Granule containing physiologically-active substance, method for preparing same and use thereof |
| EP0376331A3 (en) * | 1988-12-29 | 1991-03-13 | Asahi Kogaku Kogyo Kabushiki Kaisha | Slow release drug delivery granules and process for production thereof |
| US5861172A (en) * | 1991-05-08 | 1999-01-19 | Laboratorios Beecham Sa | Pharmaceutical formulations of compacted granulates of β-lactam antibiotics |
| US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
| US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
| HU219121B (en) * | 1992-03-12 | 2001-02-28 | Smithkline Beecham Plc. | Condensed indole derivatives and process for their preparation and pharmaceutical compositions of 5-ht4-receptor antagonistic activity containing them |
| GB9408117D0 (en) * | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| DE4418837A1 (en) * | 1994-05-30 | 1995-12-07 | Bayer Ag | Thermal granulation process |
| FR2740357B1 (en) * | 1995-10-25 | 1997-11-28 | Rhone Poulenc Chimie | WATER REDISPERSABLE GRANULES COMPRISING A LIQUID-ACTIVE MATERIAL AND A NON-IONIC ALCOXYL SURFACTANT |
| CZ2003366A3 (en) * | 2000-08-07 | 2004-04-14 | Laboratoire Glaxosmithkline S. A. S. | Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| DK1313481T3 (en) * | 2000-08-08 | 2008-01-28 | Smithkline Beecham Plc | Pharmaceutical composition comprising condensed indole compounds |
| NZ535261A (en) * | 2000-08-08 | 2004-12-24 | Smithkline Beecham P | A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide |
| US6666298B2 (en) * | 2001-11-21 | 2003-12-23 | John Volkman | Hanging scaffold support |
-
2003
- 2003-01-22 AT AT03700915T patent/ATE329581T1/en active
- 2003-01-22 PL PL371963A patent/PL206544B1/en not_active IP Right Cessation
- 2003-01-22 RU RU2004127450/15A patent/RU2329789C2/en not_active IP Right Cessation
- 2003-01-22 PT PT03700915T patent/PT1476136E/en unknown
- 2003-01-22 US US10/503,750 patent/US20050075335A1/en not_active Abandoned
- 2003-01-22 EP EP03700915A patent/EP1476136B1/en not_active Expired - Lifetime
- 2003-01-22 BR BR0307666-0A patent/BR0307666A/en not_active IP Right Cessation
- 2003-01-22 DE DE60306120T patent/DE60306120T2/en not_active Expired - Lifetime
- 2003-01-22 JP JP2003567377A patent/JP2005523276A/en active Pending
- 2003-01-22 ES ES03700915T patent/ES2263949T3/en not_active Expired - Lifetime
- 2003-01-22 KR KR1020047012580A patent/KR100967782B1/en not_active IP Right Cessation
- 2003-01-22 CA CA002475659A patent/CA2475659A1/en not_active Abandoned
- 2003-01-22 DK DK03700915T patent/DK1476136T3/en active
- 2003-01-22 NZ NZ534333A patent/NZ534333A/en not_active IP Right Cessation
- 2003-01-22 AU AU2003202058A patent/AU2003202058B2/en not_active Ceased
- 2003-01-22 MX MXPA04007857A patent/MXPA04007857A/en active IP Right Grant
- 2003-01-22 WO PCT/GB2003/000217 patent/WO2003068193A1/en active IP Right Grant
-
2004
- 2004-08-11 CO CO04078329A patent/CO5611095A2/en not_active Application Discontinuation
- 2004-08-12 IS IS7398A patent/IS2393B/en unknown
- 2004-09-13 NO NO20043834A patent/NO20043834L/en not_active Application Discontinuation
-
2005
- 2005-04-28 HK HK05103665A patent/HK1072359A1/en not_active IP Right Cessation
-
2006
- 2006-08-28 CY CY20061101205T patent/CY1106148T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004127450A (en) | 2005-04-10 |
| EP1476136B1 (en) | 2006-06-14 |
| BR0307666A (en) | 2005-01-11 |
| NO20043834L (en) | 2004-10-26 |
| RU2329789C2 (en) | 2008-07-27 |
| AU2003202058B2 (en) | 2009-05-28 |
| IS2393B (en) | 2008-08-15 |
| CA2475659A1 (en) | 2003-08-21 |
| MXPA04007857A (en) | 2004-10-15 |
| DE60306120T2 (en) | 2006-11-09 |
| CO5611095A2 (en) | 2006-02-28 |
| PT1476136E (en) | 2006-10-31 |
| EP1476136A1 (en) | 2004-11-17 |
| PL371963A1 (en) | 2005-07-11 |
| DK1476136T3 (en) | 2006-10-09 |
| WO2003068193A1 (en) | 2003-08-21 |
| PL206544B1 (en) | 2010-08-31 |
| NZ534333A (en) | 2006-05-26 |
| ES2263949T3 (en) | 2006-12-16 |
| DE60306120D1 (en) | 2006-07-27 |
| KR100967782B1 (en) | 2010-07-05 |
| US20050075335A1 (en) | 2005-04-07 |
| KR20040097996A (en) | 2004-11-18 |
| ATE329581T1 (en) | 2006-07-15 |
| IS7398A (en) | 2004-08-12 |
| AU2003202058A1 (en) | 2003-09-04 |
| HK1072359A1 (en) | 2005-08-26 |
| JP2005523276A (en) | 2005-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106148T1 (en) | PHARMACEUTICAL COMPOSITION PEPILAMVANOUS N-((1-N-BUTYL-4-PIPEPIDINYL) METHYL)-3,4-DIHYDRO-2H-(1,3)OXAZINO(3,2-A)INDOLE-10-CARBOXAMIDE OR SALT AND METHOD FOR FRIDAY SHE RECEIVING DRY GRANULATION | |
| CY1117470T1 (en) | SOLID DOSAGE PREPARATIONS WITH IMPROVED ANIMAL ADJUSTMENT | |
| CY1114708T1 (en) | PYRAZOLO-KINAZOLINE PRODUCERS, PROCEDURE FOR THEIR PREPARATION AND THEIR USE AS MICROSOFT | |
| CY1106693T1 (en) | PELLETS CONTAINING VENLAFAXIN HYDROCHLORIDE | |
| DK1675591T3 (en) | Pharmaceutical composition comprising a monoamine neurotransmitter reuptake inhibitor and an acetylcholinesterase inhibitor | |
| WO1999007351A3 (en) | Indole derivatives and their use as mcp-1 antagonists | |
| TR200102110T2 (en) | Combinations of formoterol and fluicasone propionate for asthma. | |
| NO20081365L (en) | New crystalline form of a pyridazino [4,5-b] indole derivative | |
| CY1108854T1 (en) | IVABRADININ COMPOSITE MEDICINAL PRODUCTS | |
| TR200401793T4 (en) | Perindopril salt and pharmaceutical compositions containing it. | |
| CY1105028T1 (en) | SUBSTITUTED C-IMIDAZO-[1,2-A]PYRIDIN-3-YL-METHYLAMINES | |
| EA200500388A1 (en) | METHOD OF OBTAINING DRY POWDER COMPOSITIONS FOR INHALATION | |
| CY1114311T1 (en) | Immediate Release Therapeutic Systems for Improved Oral Absorption 7 - [(E) -TRIT-BUTYLOXYMINOMETHYL] | |
| DE60313359D1 (en) | FENOFIBRATEDIC PHARMACEUTICAL COMPOSITION AND ITS PHYSIOLOGICALLY COMPATIBLE SALTS AND DERIVATIVES | |
| CY1115709T1 (en) | PHARMACEUTICAL FORM CONTENT FLUPERTINE WITH CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE | |
| HRP20010277B1 (en) | Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative | |
| DE60302157D1 (en) | OPIOID RECEPTOR ANTAGONISTS | |
| CY1105019T1 (en) | SUBSTITUTED C-IMIDAZO-[1,2-A]PYRIDIN-3-YL-METHYLAMINES | |
| CY1105168T1 (en) | BIPHASIC COMPOSITION WITH TRAMADOL | |
| CY1105165T1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND 4-OXOBUTANOIC ACID AND ITS USE FOR THE TREATMENT OF DIABETES | |
| EA200300727A1 (en) | DERIVATIVES OF 2H-1-BENZOPIRANE, METHODS OF THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| ATE326451T1 (en) | QUINAZOLINE DERIVATIVES AND THERAPEUTIC USES THEREOF | |
| DE69813263D1 (en) | HYDRAZONO-BENZAZULEN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND INTERMEDIATE PRODUCTS | |
| GEP20094649B (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
| FI965097A (en) | Substituted alkyldiamine derivatives and their use as tachykinin antagonists |